RxSight, Inc. logo

RxSight, Inc.

RXST

NASDAQHealthcareMedical - Devices

Previous close

$6.25

+$0.16 · +2.63%

Aug 21, 4:00 PM ET

RXST company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

57

Fair Value

Momentum

22

Weakening

Sentiment

69

Bullish

Risk resilience

30

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Aziz Mottiwala
Listed since
Jul 30, 2021
Employees
461

Market position

Day range

Current $6.25

52-week range

Current $6.25

Open
$6.10
Previous close
$6.09
Volume
1.54M
1.52× average
Average volume
1.02M
Average daily volume
Market cap
258.73M USD
Beta
1.13
Market reference 1
50-day average
$5.6346
+10.92% above average
200-day average
$7.6942
-18.77% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-5.53×
P/B (TTM)
0.98×
P/S (TTM)
2.03×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
77.50%
Operating margin
-43.20%
Net margin
-36.80%

Financial health

Debt / equity
0.04×

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+14.34%
11 comparable reports
Latest EPS result
-0.29
Estimate -0.33 · Beat by 11.95%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.13-0.23-0.32-0.42Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual -0.15, estimate -0.166, surprise +9.57%, Beat. Q2 2025, reported May 7, 2025: actual -0.2, estimate -0.217, surprise +7.70%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.29, estimate -0.254, surprise -14.09%, Miss. Q4 2025, reported Nov 5, 2025: actual -0.24, estimate -0.34, surprise +29.41%, Beat. Q1 2026, reported Feb 25, 2026: actual -0.22, estimate -0.335, surprise +34.27%, Beat. Q2 2026, reported May 6, 2026: actual -0.38, estimate -0.299, surprise -27.14%, Miss. Q3 2026, reported Aug 5, 2026: actual -0.29, estimate -0.329, surprise +11.95%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.29, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates41.92M35.84M29.75M23.67MQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 40.21M USD, estimate 40.31M USD, surprise -0.24%, Miss. Q2 2025, reported May 7, 2025: actual 37.9M USD, estimate 38.08M USD, surprise -0.49%, Miss. Q3 2025, reported Aug 7, 2025: actual 33.64M USD, estimate 34.79M USD, surprise -3.32%, Miss. Q4 2025, reported Nov 5, 2025: actual 30.3M USD, estimate 25.28M USD, surprise +19.87%, Beat. Q1 2026, reported Feb 25, 2026: actual 32.61M USD, estimate 30.17M USD, surprise +8.09%, Beat. Q2 2026, reported May 6, 2026: actual 30.89M USD, estimate 29.75M USD, surprise +3.84%, Beat. Q3 2026, reported Aug 5, 2026: actual 33.74M USD, estimate 32.55M USD, surprise +3.66%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 27.19M USD, surprise —, Comparison unavailable.

RXST peers

ETFs holding RXST

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research RXST

research.disclaimer